These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30719834)

  • 1. Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells.
    Park SM; Hwang CY; Cho SH; Lee D; Gong JR; Lee S; Nam S; Cho KH
    FEBS J; 2019 Apr; 286(7):1305-1318. PubMed ID: 30719834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
    Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
    Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of genes responsible for cetuximab sensitization in colorectal cancer cells using CRISPR-Cas9.
    Hu TT; Yang JW; Yan Y; Chen YY; Xue HB; Xiang YQ; Ye LC
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33048115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
    Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Ye S; Hu X; Ni C; Jin W; Xu Y; Chang L; Zhou H; Jiang J; Yang L
    Mol Cancer Ther; 2020 Mar; 19(3):956-965. PubMed ID: 31924740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
    Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
    BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in
    Wu DW; Lin PL; Wang L; Huang CC; Lee H
    Theranostics; 2017; 7(5):1114-1132. PubMed ID: 28435452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
    Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
    Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer.
    Li C; Singh B; Graves-Deal R; Ma H; Starchenko A; Fry WH; Lu Y; Wang Y; Bogatcheva G; Khan MP; Milne GL; Zhao S; Ayers GD; Li N; Hu H; Washington MK; Yeatman TJ; McDonald OG; Liu Q; Coffey RJ
    Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2852-E2861. PubMed ID: 28320945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway.
    Wang C; Yang M; Gu X; Gu Y
    Bioengineered; 2021 Dec; 12(1):6594-6605. PubMed ID: 34516351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
    Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
    Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The microRNA-429/DUSP4 axis regulates the sensitivity of colorectal cancer cells to nintedanib.
    Cheng G; Li Y; Liu Z; Song X
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33495832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer.
    Yuan Y; Sun X; Liu M; Li S; Dong Y; Hu K; Zhang J; Xu B; Ma S; Jiang H; Hou P; Lin Y; Gan L; Liu T
    Acta Biochim Biophys Sin (Shanghai); 2023 Jun; 55(9):1467-1478. PubMed ID: 37310146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer.
    Peng K; Liu R; Yu Y; Liang L; Yu S; Xu X; Liu T
    Biomed Pharmacother; 2018 Jan; 97():1138-1146. PubMed ID: 29136952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.